ACVR2B

Across TCGA pan-cancer cohorts, ACVR2B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACVR2B data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACVR2B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ACVR2B expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where ACVR2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	II,III,IV	0.481	0.940	.001	53	view →
LUAD	DFS	Tertile	III,IV	0.385	0.986	.024	6	view →
GBM	DFS	Median	All	0.245	0.531	.015	4	view →
PDAC	OS	Median	III,IV	0.645	0.182	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACVR2B–CCRCC (OS)

Open the CCRCC breakdown →